stigators, will result in a negative relationship between aggregate TGPP and number of sites.Some of these trial-level fixed costs are likely to be country specific, reflecting factors such as national institutional review boards, import duties and tariffs, medical licensing conventions, or other costs of conforming to a given country???s regulatory framework and medical infrastructure.